Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide

التفاصيل البيبلوغرافية
العنوان: Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide
المؤلفون: Yi-Tien Li, Gilbert-Aaron Lee, Cheng Yu Chen, Yu Wei Chang, Yung Chieh Chen, Wan-Li Lin, Duen Pang Kuo, Justin Bo-Kai Hsu, Shiu-Wen Huang
المصدر: International Journal of Nanomedicine
سنة النشر: 2021
مصطلحات موضوعية: PD-L1, medicine.medical_treatment, Cell, Biophysics, Pharmaceutical Science, Contrast Media, Bioengineering, Ferric Compounds, B7-H1 Antigen, Biomaterials, Mice, In vivo, Cell Line, Tumor, Drug Discovery, medicine, Temozolomide, Animals, Humans, Magnetite Nanoparticles, lipid-coated nanoparticle, Original Research, medicine.diagnostic_test, biology, Chemistry, Organic Chemistry, glioblastoma, Magnetic resonance imaging, General Medicine, Immunotherapy, Lipids, Magnetic Resonance Imaging, In vitro, medicine.anatomical_structure, Cell culture, SPIO, Cancer research, biology.protein, superparamagnetic iron oxide, Magnetic Iron Oxide Nanoparticles, medicine.drug, MRI
الوصف: Background: Targeted superparamagnetic iron oxide (SPIO) nanoparticles are a promising tool for molecular magnetic resonance imaging (MRI) diagnosis. Lipid-coated SPIO nanoparticles have a nonfouling property that can reduce nonspecific binding to off-target cells and prevent agglomeration, making them suitable contrast agents for molecular MRI diagnosis. PD-L1 is a poor prognostic factor for patients with glioblastoma. Most recurrent glioblastomas are temozolomide-resistant. Diagnostic probes targeting PD-L1 could help early diagnosis and be used to predict the responses of targeted PD-L1 immunotherapy in patients with primary and recurrent glioblastoma. In this study, we conjugated lipid-coated SPIO nanoparticles with PDL1 antibodies to identify PDL1 expression in glioblastoma or temozolomide-resistant glioblastoma by using MRI.Results: The synthesized PD-L1 antibody–conjugated SPIO (PDL1-SPIO) nanoparticles were characterized using dynamic light scattering, zeta potential assays, transmission electron microscopy images, in vitro cell affinity assay, and in vivo MRI analysis. These data demonstrated that PDL1-SPIO has a specific binding capacity to PD-L1 of the mouse glioblastoma cell line (GL261). The presence and quantity of PDL1-SPIO in temozolomide-resistant glioblastoma cells and tumor tissue were confirmed through Prussian blue staining and in vivo T2* map MRI, respectively.Conclusions: These findings revealed that PDL1-SPIO can specifically target temozolomide-resistant glioblastoma with PD-L1 expression and can be quantified with MRI analysis, thereby making it suitable for the diagnosis of PD-L1 expression in temozolomide-resistant glioblastoma in vivo.
تدمد: 1178-2013
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c25272e9b08a6d23de0da9c0d93490
https://pubmed.ncbi.nlm.nih.gov/34366665
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....d3c25272e9b08a6d23de0da9c0d93490
قاعدة البيانات: OpenAIRE